Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Chronic Coronary Syndromes

ESC 2024 | REC-CAGEREE I Trial: Drug Coated Balloon with Bailout Stenting vs. Intended DES for de Novo Lesion Treatment

DES stenting is currently the standard treatment. The development of balloon technology and the coating drugs have...
Dr. Omar Tupayachi -
Ver más
Bifurcations

Stent Optimal Minimal Area and Stent Underexpansion Impact in 2-Stent Left Main Treatment

The upfront 2-stent strategy for left main bifurcation treatment presents a technical challenge and has been associated...
Dr. Andrés Rodríguez -
Ver más
Chronic Ischemic cardiopathy

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of...
solaci -
Ver más
Coronary disease

Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis

Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat...
solaci -
Ver más
Coronary disease

Coronary Angioplasty with Sirolimus Eluting Stents

At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug...
solaci -
Ver más
Coronary disease

BIONYX: Onyx vs. Orsiro At 5 Years

Onyx is a zotarolimus-eluting stent (ZES), designed with thin struts and a platinum core that enhances its...
solaci -
Ver más
Coronary disease

EuroPCR 2024 | 2 Year Outcomes of the New Sirolimus Eluting Bioadaptor vs Resolute Onyx Zotarolimus Elulting Stent

Stent related adverse events after the first year see a constant 2-3% annual increase, reaching 20% by...
solaci -
Ver más
Coronary disease

Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes

In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

AHA 2024 | VANISH2 Trial

Dr. Omar Tupayachi - 0
Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

Dr. Omar Tupayachi - 0
It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Dr. Omar Tupayachi - 0
Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad